STOCK TITAN

Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 14, 2020, at 1:30 p.m. ET. CEO Kevin Gorman and CFO Matt Abernethy will lead the presentation. The event will be webcast live and can be accessed via the company's website. A replay will be available approximately one hour post-event and archived for one month. Neurocrine, based in San Diego, specializes in treatments for neurological, endocrine, and psychiatric disorders, with multiple FDA-approved products in its portfolio.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 18th Annual Global Healthcare Conference at 1:30 p.m. ET on Monday, September 14, 2020. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, with three pivotal and five mid-stage clinical programs in multiple therapeutic areas. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn(*in collaboration with AbbVie)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-morgan-stanley-18th-annual-global-healthcare-conference-301125819.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences present at the Morgan Stanley Global Healthcare Conference?

Neurocrine Biosciences will present on September 14, 2020, at 1:30 p.m. ET.

Who will represent Neurocrine Biosciences at the conference?

CEO Kevin Gorman and CFO Matt Abernethy will represent Neurocrine Biosciences.

How can I watch Neurocrine Biosciences' presentation at the conference?

The presentation will be webcast live and can be accessed on Neurocrine's website.

Is there a replay available for Neurocrine's conference presentation?

Yes, a replay will be available about one hour after the presentation and will be archived for one month.

What is Neurocrine Biosciences known for?

Neurocrine Biosciences is known for developing treatments for neurological, endocrine, and psychiatric disorders.

Neurocrine Biosciences Inc

NASDAQ:NBIX

NBIX Rankings

NBIX Latest News

NBIX Stock Data

13.83B
99.72M
1%
96.03%
4.19%
Drug Manufacturers - Specialty & Generic
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO